Inovio Pharma (INO) Misses Q3 EPS by 89c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Inovio Pharmaceuticals (INO) PT Lowered to $6 at RBC Capital
November 15, 2024 6:33 AM ESTRBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $6.00 (from $7.00) while maintaining a Sector Perform rating.
The analyst comments "INOs 3Q print affirms INO-3107 in RRP as the companys primary focus during a time... More
